摘要
目的:观察乌司他丁在急性胰腺炎临床治疗中的作用效果,分析其临床治疗价值。方法:选取我院治疗的急性胰腺炎患者178例,根据治疗方法不同分为观察组和对照组,每组89例。对照组患者采用奥曲肽治疗,观察组患者采用乌司他丁与奥曲肽联合治疗。观察并比较治疗前后患者APACHEⅡ评分和血清炎症因子变化及临床疗效。结果:入院时,两组血清CRP、IL-1、IL-6、TNF-α、APACHEⅡ评分无统计差异(P>0.05),治疗后,组内CRP、IL-1、IL-6、TNF-α、APACHEⅡ评分明显下降(P<0.05);观察组CRP、IL-1、IL-6、TNF-α、APACHEⅡ评分显著低于参照组(P<0.05);观察组临床总有效率(86.52%)显著高于参照组(71.91%),观察组并发症(12.36%)明显低于参照组(24.72%),P<0.05,组间有统计差异。结论:乌司他丁能够显著提升急性胰腺炎的临床疗效,促进患者康复,其作用机制可能与抑制炎症因子表达有关。
Objective: To observe the clinical effect of ulinastatin on acute pancreatitis and the serum levels of inflammatory fac- tors in patients. Methods: 178 cases with acute pancreatitis who were treated in our hospital were selected and according to the different treatment methods, the patients were divided into the observation group and the control group, with 89 cases in each group. The patients in the observation group were treated with UTI and octreotide, while the patients in the control group were treated with octreotide. Then the changes of APACHE II score and serum inflammatory factors of patients were observed and compared before and after treatment. Results: At admission, the levels of serum CRP, IL-1, IL-6, TNF-et and APACHE II score were without statistical differences (P〉 0.05). After treatment, the CRP, IL-1, IL-6, TNF-ct and APACHE II score in the two groups significantly decreased (P〈0.05). The CRP, IL-1, IL-6, TNF-tx and APACHE II scores in the observation group were significantly lower than those of the control group (P 〈0.05). The to- tal clinical efficiency rate of the observation group was 86.52%, which was significantly higher than 71.91 in the control group, and the complications in the observation group was 12.36%, which was significantly lower than 24.72% in the control group, and the differences were statistically significant (P〈0.05). Conclusion: Ulinastatin can significantly improve the clinical efficacy of acute pancreatitis, and promote the rehabilitation of patients, and its mechanism may be related to inhibition of inflammatory cytokine expressions.
出处
《现代生物医学进展》
CAS
2017年第7期1331-1334,共4页
Progress in Modern Biomedicine